Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 1/20 | 0.53 |
| ▸ | MAOA | P21397 | 5/20 | 0.51 |
| ▸ | MAOB | P27338 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.51 |
| ▸ | CALML3 | P27482 | 1/20 | 0.51 |
| ▸ | SDHA | P31040 | 1/20 | 0.51 |
| ▸ | F10 | P00742 | 5/20 | 0.49 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7699963 | 1.00 | GRM2 (0.53) | GRM2MAOAMAOBLMNAPTGS1 | |
| SCHEMBL7608721 | 1.00 | GRM2 (0.53) | GRM2MAOAMAOBLMNAPTGS1 | |
| SCHEMBL9550280 | 0.90 | GRM2 (0.56) | GRM2MAOAMAOBLMNAPTGS1 | |
| SCHEMBL10395515 | 0.88 | MAOA (0.52) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL9521339 | 0.84 | MAOA (0.53) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL10394771 | 0.84 | MAOA (0.53) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL9521097 | 0.83 | MAOA (0.57) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL7531429 | 0.83 | MAOA (0.57) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL10753989 | 0.82 | MAOA (0.56) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL10394776 | 0.81 | MAOA (0.51) | MAOAMAOBLMNAPTGS1CALML3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020115669-A1 | Oxazolidinone chemotherapeutic agents | ABBOTT LABORATORIES | 2002-08-22 | — | — | US | claimed |
| WO-2002018354-A1 | OXAZOLIDINONES AND THEIR USE AS ANTIBACTERIAL AGENTS | ABBOTT LABORATORIES (US) | 2002-03-07 | — | — | WO | claimed |
| WO-2002018354-A1 | OXAZOLIDINONES AND THEIR USE AS ANTIBACTERIAL AGENTS | ABBOTT LABORATORIES (US) | 2002-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020115669-A1 | Oxazolidinone chemotherapeutic agents | TOP1, OXA1L, TK1 | GRM2 3895/4885MAOA 3161/4885MAOB 2432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.